Rheumatology
RCT: Short-term effectiveness of high-load compared with low-load strengthening exercise on self-reported function in patients with hypermobile shoulders.
9 Jun, 2022 | 10:44h | UTC
Commentary on Twitter
? LATEST #OriginalResearch
⚠️ Hypermobility spectrum disorder and shoulder symptoms
Are high-load strengthening exercises more effective at improving shoulder function than low-load⁉️
NEW #OpenAccess randomised controlled trial ?
➡️ https://t.co/qQd8dDCdyW pic.twitter.com/jLyI3WxYRq
— British Journal of Sports Medicine (BJSM) (@BJSM_BMJ) June 4, 2022
Podcast: Hand and wrist pain.
8 Jun, 2022 | 10:44h | UTC#339 Hand and Wrist Pain with Dr. Ted Parks – The Curbsiders
International perspectives on joint hypermobility: a synthesis of current science to guide clinical and research directions.
7 Jun, 2022 | 11:23h | UTC
Commentary on Twitter
Line this up for your weekend read, what a team to work with!!
Lead by @leslieln, @jvsimmonds01, @PaceyVerity, @ClifftonChan, Inge De Wandele, Leis Rombaut.
International Perspectives on Joint #Hypermobility, #openaccess ??????
https://t.co/zqqfqnBZtL#AcademicTwitter pic.twitter.com/544cIjH68R
— A/Prof Cylie Williams (@CyliePaedspod) June 3, 2022
#EULAR2022 – RCT: Low dose, add-on prednisolone in patients with rheumatoid arthritis over 65 years.
6 Jun, 2022 | 11:51h | UTCCommentaries:
Chronic, low-dose glucocorticoid benefits outweigh harms in senior patients with RA – medwire News
Trial Upends Guidelines on Long-Term Steroids in Rheumatoid Arthritis — Vindication for clinicians who ignored official recommendations – MedPage Today (free registration required)
Difficult and complicated oral ulceration: an expert consensus guideline for diagnosis.
6 Jun, 2022 | 11:19h | UTC
Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sjogren syndrome.
3 Jun, 2022 | 11:37h | UTC
M-A: Prospective studies comparing structured vs. nonstructured diagnostic protocol evaluations among patients with fever of unknown origin.
3 Jun, 2022 | 11:00h | UTC
Review: Skeletal aging.
2 Jun, 2022 | 10:50h | UTCSkeletal Aging – Mayo Clinic Proceedings
BSR guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
1 Jun, 2022 | 12:05h | UTCExecutive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs – Rheumatology
Editorial: Chance encounters, overdiagnosis, and overtreatment in orthopedic surgery.
30 May, 2022 | 11:43h | UTC
Commentary on Twitter
"Shoulder, back, and knee pain are part of life and part of aging; when they overlap with age-related MRI findings, which probably do not have anything to do with the presenting complaint, we get overdiagnosis."https://t.co/XLG5RQ7vfo
— Derek Griffin (@DerekGriffin86) May 27, 2022
Guidelines on the management of lumbar spinal stenosis.
26 May, 2022 | 10:44h | UTC
M-A: Systemic pharmacological treatments for chronic plaque psoriasis.
24 May, 2022 | 08:00h | UTC
Review | Disorders of ubiquitylation: unchained inflammation.
18 May, 2022 | 10:36h | UTCDisorders of ubiquitylation: unchained inflammation – Nature Reviews Rheumatology (if the link is paywalled, try this one in PMC)
Commentary on Twitter
New content online! Disorders of ubiquitylation: unchained inflammation https://t.co/L8dbPDcA6T pic.twitter.com/LlbRreOQzc
— NatRevRheumatol (@NatRevRheumatol) May 6, 2022
Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis.
17 May, 2022 | 10:56h | UTC
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
17 May, 2022 | 10:54h | UTC
Commentary on Twitter
Our 2022 EULAR points to consider on Therapeutic drug monitoring of biologics just published in @ARD_BMJ
A real pleasure being part of this steering group & collaborative taskforce expertly led by @ProfJohnIsaacs
Clear points for practice& research?https://t.co/YesEjajaIK pic.twitter.com/cQw8o1bjUw
— Meghna Jani (@MeghnaJani) May 15, 2022
M-A: Worldwide incidence and prevalence of Antineutrophil Cytoplasmic Antibody (ANCA) associated vasculitis.
17 May, 2022 | 10:20h | UTC
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases.
16 May, 2022 | 02:11h | UTC
Commentary on Twitter
2022 #EULAR points to consider for remote care in #rheumatic and #musculoskeletal diseaseshttps://t.co/oB0Fo0wzoM pic.twitter.com/LS95rSvCmh
— ARD & RMD Open (@ARD_BMJ) April 27, 2022
Nutritional recommendations for patients undergoing prolonged glucocorticoid therapy.
13 May, 2022 | 11:05h | UTC
Commentary on Twitter
NEW: Narrative review from @esteves_gp @eimeardol et al summarises evidence regarding #nutritional recommendations during GC therapy and highlights gaps in the literature.
✅ Targeted nutritional strategies may help alleviate adverse effects of GCs.? https://t.co/8NpIxkYmIv pic.twitter.com/RArjGTw6sA
— Rheumatology & Rheumatology Advances in Practice (@RheumJnl) April 22, 2022
Review: Vertebroplasty for osteoporotic vertebral fracture – Three among four double-blind studies which used a sham procedure did not confirm the benefit suggested by previous studies.
13 May, 2022 | 10:44h | UTCVertebroplasty for osteoporotic vertebral fracture – RMD Open
Phase 2/3 RCT: Tocilizumab in patients with new onset polymyalgia rheumatica reduces flares in a protocol of rapid glucocorticoid tapering (from 20 mg to 0 mg over 11 weeks).
13 May, 2022 | 10:42h | UTCTocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Systematic Review: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
11 May, 2022 | 11:04h | UTC
Phase 2 RCT: Anti-tumor necrosis factor therapy for early-stage Dupuytren’s disease.
9 May, 2022 | 01:38h | UTCNews Release: Breakthrough in treatment for Dupuytren’s disease – University of Oxford
Commentary: Treatment for finger-bending disease may be ‘gamechanger’ – The Guardian
Commentary on Twitter
NEW RESEARCH—Intranodular injections of anti-tumour necrosis factor therapy (adalimumab) for early-stage Dupuytren's disease: a phase 2b, randomised, double-blind, placebo-controlled trial https://t.co/Jz9QUJEzS8 #LancetRheumatology #OpenAccess pic.twitter.com/mcZj9GK4l4
— The Lancet Rheumatology (@TheLancetRheum) May 4, 2022
2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.
5 May, 2022 | 10:22h | UTC
Phase 2/3 RCT: Tocilizumab in patients with new onset polymyalgia rheumatica.
4 May, 2022 | 08:04h | UTCTocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary on Twitter
A 24 week RCT in patients with new-onset #PMR evaluating tocilizumab vs. placebo:
▶️ Primary Outcome: 63.2% of Toci vs. 11.8% in the PLC group reached glucocorticoid free remission at week 16
▶️ time to relapse: 130 days in Toci vs 82d in PLC grouphttps://t.co/4ylx2CqebR— ARD & RMD Open (@ARD_BMJ) February 28, 2022
Phase 2 RCT: Efficacy and safety of Deucravacitinib, a selective TYK2 inhibitor, in psoriatic arthritis.
4 May, 2022 | 08:09h | UTC
Commentary on Twitter
Phase II trial: selective TYK2 inhibitor deucravacitinib in 203 patients with PsA:
▶️ Prim outcome met: ACR-20 response deucravacitinib 6 mg daily 52.9% / 12 mg daily 62.7% vs placebo 31.8% at week 16
▶️ Fig: adjusted mean change from baseline in HAQ-DIhttps://t.co/YR1ZbfF0gy pic.twitter.com/WNCjEGpj27— ARD & RMD Open (@ARD_BMJ) March 4, 2022